Chardan analyst Geulah Livshits raised the firm’s price target on Palvella Therapeutics (PVLA) to $240 from $210 and keeps a Buy rating on the shares. The company highlighted progress across its expanding topical therapy pipeline when reporting Q4 results, the analyst tells investors in a research note. The firm says Palvella’s cash position should take it through initial approval and launch in microcystic lymphatic malformations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $210 from $200 at Oppenheimer
- Palvella Highlights 2025 Results and SELVA Phase 3 Progress
- PVLA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Palvella Therapeutics price target raised to $270 from $255 at H.C. Wainwright
- Buy Rating Driven by Strong Phase 3 SELVA Data and Favorable FDA Pathway for QTORIN in Rare MLM Indication